Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 1374

Supplemental Proposed Jury Instructions by F. Hoffmann-LaRoche LTD, Roche Diagnostics GmbH, Hoffmann LaRoche Inc.. (Fleming, Thomas)

Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Doc. 1374

Case 1:05-cv-12237-WGY

Document 1374

Filed 10/14/2007

Page 1 of 4

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS ) ) ) ) Civil Action No.: 05-CV-12237 ) WGY ) ) ) ) ) ) )

AMGEN INC., Plaintiff, vs. F. HOFFMANN-LA ROCHE, LTD, ROCHE DIAGNOSTICS GmbH, and HOFFMANN-LA ROCHE INC., Defendants.

SUPPLEMENTAL DEFENDANTS' PROPOSED FINAL JURY INSTRUCTION Defendants Hoffmann-La Roche, Ltd, Roche Diagnostics GmbH, and Hoffmann-La Roche Inc. respectfully request that the Court read the attached Supplemental Final Jury Instruction No. 1 to the jury in addition to the previously submitted Defendants' Supplemental Proposed Final Jury Instructions, filed October 10, 2007 (D.I. 1343) at the conclusion of trial. Defendants suggest that a logical place for this instruction would be between Instructions 4.14 and 4.15 of D.I. 1343. Dated: October 14, 2007 Boston, Massachusetts Respectfully submitted, F. HOFFMANN-LA ROCHE, LTD, ROCHE DIAGNOSTICS GMBH, and HOFFMANN-LA ROCHE INC. By its attorneys, /s/ Vladimir Drozdoff_________ Leora Ben-Ami (pro hac vice) Patricia A. Carson (pro hac vice) Thomas F. Fleming (pro hac vice) Howard S. Suh (pro hac vice) Christopher Jagoe (pro hac vice) Peter Fratangelo (BBO# 639775) KAYE SCHOLER LLP 425 Park Avenue New York, New York 10022 Tel. [phone]

Dockets.Justia.com

Case 1:05-cv-12237-WGY

Document 1374

Filed 10/14/2007

Page 2 of 4

Lee Carl Bromberg (BBO# 058480) Julia Huston (BBO# 562160) Keith E. Toms (BBO# 663369) Nicole A. Rizzo (BBO# 663853) BROMBERG & SUNSTEIN LLP 125 Summer Street Boston, MA 02110 Tel. [phone] [e-mail]

2

Case 1:05-cv-12237-WGY

Document 1374

Filed 10/14/2007

Page 3 of 4

SUPPLEMENTAL FINAL JURY INSTRUCTION NO. 1 FIGURE 6 OF THE PATENTS-IN-SUIT The sequence shown in Figure 6 of the patents-in-suit has a DNA sequence coding for 166 amino acids. The patent specification states that "the primary structural conformation (amino acid sequence) of mature human EPO as including 166 specified amino acid residues." `933 patent, col. 21, ln. 3-5. Thus, the protein described in Figure 6 cannot be anything other than 166 amino acids.1

Amgen Inc. v. Hoechst Marion Roussel, Inc., 314 F.3d 1313, 1345 (Fed. Cir. 2003); Amgen Inc. v. Hoechst Marion Roussel, Inc., 457 F.3d 1293, 1308 (Fed. Cir. 2006). 3

1

Case 1:05-cv-12237-WGY

Document 1374

Filed 10/14/2007

Page 4 of 4

CERTIFICATE OF SERVICE I hereby certify that this document filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF). Pursuant to agreement of counsel dated September 9, 2007, paper copies will not be sent to those indicated as non registered participants. /s/ Thomas F. Fleming Thomas F. Fleming

4